SPYRE THERAPEUTICS INC (SYRE)
Health Care · Clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics · NASDAQ
Spyre is developing a portfolio of long-acting engineered antibodies and combinations targeting validated inflammatory pathways in IBD and rheumatic diseases with potential for quarterly dosing convenience.
What SPYRE THERAPEUTICS INC does
Spyre Therapeutics is a clinical-stage biotechnology company developing a pipeline of long-acting monoclonal antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases. The company's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23, engineered with Fc domain modifications for increased pharmacokinetic half-life to enable quarterly or twice-annual subcutaneous dosing. Spyre is evaluating both monotherapies and fixed-dose-combination products, with Phase 2 trials (SKYLINE in UC and SKYWAY in rheumatic diseases) currently underway.
Themes: ["IBD (inflammatory bowel disease) therapeutics","Rheumatic diseases (rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis)","Monoclonal antibodies","Combination immunotherapies","Long-acting biologics"]
Fundamentals
- Price$98.75 as of 2026-07-09 close
- Market cap$8.6B as of 2026-07-10
- 1-year return+496.7% as of 2026-07-09 close
- Net margin-22158.5% as of 2026-07-10
- ROE-31.3% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta2.97 as of 2026-07-10
Key risks (from latest filing)
["Clinical development and regulatory risk: SPY001, SPY002, SPY003, and SPY072 are all in Phase 2 development; failure to demonstrate efficacy and safety in ongoing SKYLINE and SKYWAY trials could halt pipeline progress","Competitive landscape: Established first-generation therapies (Vedolizumab, Risankizumab, TNF inhibitors) and other development-stage combination therapies already compete in IBD and rheumatic disease markets","Unprofitability and cash burn: The company has negative net margins and is currently unprofitable with significant ongoing clinical development expenses and limited near-term revenue"]
Competitors & peers
- Takeda Pharmaceutical (IBD biologics including Vedolizumab)
- AbbVie (TNF inhibitors and IL-23 inhibitors)
- Eli Lilly (IL-23 inhibitors)
- Bristol Myers Squibb (IBD biologics)
- Amgen (IBD and rheumatic disease biologics)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.